On A Roll: Arena Continues Streak Of Positive Data With Small Crohn's Pain Study

Arena announced encouraging data from a small Phase IIa study for olorinab (APD371) in abdominal pain associated with Crohn's disease as the company continues a streak of good news after two of its more advanced clinical-stage programs posted positive results.